Zacks Research Issues Pessimistic Outlook for RDY Earnings

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Equities research analysts at Zacks Research dropped their FY2026 earnings per share (EPS) estimates for Dr. Reddy’s Laboratories in a research note issued on Wednesday, February 11th. Zacks Research analyst Team now anticipates that the company will post earnings of $0.64 per share for the year, down from their prior estimate of $0.69. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.80 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2026 earnings at $0.09 EPS, Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.13 EPS, Q4 2027 earnings at $0.09 EPS, FY2027 earnings at $0.56 EPS, Q3 2028 earnings at $0.16 EPS and FY2028 earnings at $0.63 EPS.

Separately, Weiss Ratings raised shares of Dr. Reddy’s Laboratories from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, January 30th. Two analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Dr. Reddy’s Laboratories has an average rating of “Moderate Buy” and a consensus price target of $16.90.

Dr. Reddy’s Laboratories Stock Up 1.3%

Shares of Dr. Reddy’s Laboratories stock opened at $14.22 on Thursday. The firm has a fifty day moving average of $13.78 and a two-hundred day moving average of $14.02. Dr. Reddy’s Laboratories has a one year low of $12.26 and a one year high of $16.17. The company has a market cap of $11.87 billion, a P/E ratio of 18.47, a PEG ratio of 12.51 and a beta of 0.35. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.38 and a current ratio of 1.88.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its earnings results on Wednesday, January 21st. The company reported $0.16 earnings per share for the quarter, hitting the consensus estimate of $0.16. Dr. Reddy’s Laboratories had a net margin of 16.41% and a return on equity of 15.89%. The business had revenue of $969.81 million during the quarter, compared to the consensus estimate of $963.84 million.

Hedge Funds Weigh In On Dr. Reddy’s Laboratories

A number of hedge funds have recently made changes to their positions in RDY. Robeco Institutional Asset Management B.V. increased its holdings in shares of Dr. Reddy’s Laboratories by 0.5% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 13,154,524 shares of the company’s stock worth $184,690,000 after buying an additional 70,018 shares during the last quarter. Aikya Investment Management Ltd increased its stake in Dr. Reddy’s Laboratories by 9.3% during the fourth quarter. Aikya Investment Management Ltd now owns 7,338,525 shares of the company’s stock worth $103,033,000 after acquiring an additional 623,518 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Dr. Reddy’s Laboratories by 2.0% during the third quarter. JPMorgan Chase & Co. now owns 6,027,710 shares of the company’s stock worth $84,267,000 after acquiring an additional 116,924 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Dr. Reddy’s Laboratories by 3.0% in the 3rd quarter. Vanguard Group Inc. now owns 5,123,709 shares of the company’s stock worth $71,629,000 after purchasing an additional 148,662 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in Dr. Reddy’s Laboratories by 3.7% in the fourth quarter. BNP Paribas Financial Markets now owns 4,152,566 shares of the company’s stock valued at $58,302,000 after buying an additional 149,384 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India‐based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost‐effective generic treatments for branded drugs that have lost patent protection, along with in‐house research into innovative molecule development.